TRx 0237

Drug Profile

TRx 0237

Alternative Names: leuco-methylthioninium; LMT-X; LMTM; LMTX; TRx-0237

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TauRx Pharmaceuticals
  • Class Antidementias; Small molecules
  • Mechanism of Action Synuclein inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dementia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease; Dementia
  • Phase II Progressive supranuclear palsy
  • Phase I Parkinson's disease

Most Recent Events

  • 27 Nov 2017 Updated efficacy data from a phase III trial (TRx-237-005) in Alzheimer’s disease released by TauRx Therapeutics
  • 17 Dec 2016 Top-line efficacy and adverse events data from a phase III trial in Alzheimer’s disease released by TauRx Therapeutics
  • 17 Dec 2016 TauRx Therapeutics plans a clinical trial for Alzheimer’s disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top